Rueffer U, Sieber M, Stemberg M, Gossmann A, Josting A, Koch T, Grotenhermen F, Diehl V
First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Strasse 9, 50924 Cologne, Germany.
Ann Hematol. 2003 Jul;82(7):390-6. doi: 10.1007/s00277-003-0631-3. Epub 2003 May 23.
Diagnostic laparotomy is no longer routinely performed in Hodgkin's lymphoma and noninvasive diagnosis of spleen involvement remains uncertain. In order to assess the probability of splenic involvement based on clinical parameters, we retrospectively analyzed data on patients of the German Hodgkin's Lymphoma Study Group (GHSG) who underwent staging laparotomy and for whom splenic weight and size were available. Our study included 376 patients with Hodgkin's lymphoma who underwent staging laparotomy and splenectomy according to the treatment policy of the GHSG between February 1981 and January 1993. Univariate and multivariate analyses of pretherapeutic clinical characteristics and splenic weight were performed in order to predict the probability of splenic involvement. Computed tomographic (CT) images of 25 patients were available and used to correlate radiological splenic size and pathological splenic weight. In 171 of 376 patients spleen involvement was found. Average weight of the spleens was 258 g (+/-257) ranging from 55 to 3290 g. All spleens with a weight above 2000 g showed disease involvement, while those under 150 g were never involved. In the multivariate analysis, splenic weight ( p<0.001), erythrocyte sedimentation rate ( p<0.001), and clinical stage ( p<0.01) were found to be independently prognostic for spleen involvement. Splenic weight was highly correlated with a spleen index defined as the product of length, width, and thickness measured by CT (correlation coefficient: 0.93). By applying the identified risk factors in clinically staged patients spleen involvement can be determined. Spleen weight can be estimated with the help of a spleen index. Above an index of 1000 the probability of spleen involvement is higher than 90%. This might be of outstanding importance for patients being scheduled for involved field radiation.
诊断性剖腹术在霍奇金淋巴瘤中已不再常规进行,脾脏受累的非侵入性诊断仍不明确。为了基于临床参数评估脾脏受累的可能性,我们回顾性分析了德国霍奇金淋巴瘤研究组(GHSG)接受分期剖腹术且有脾脏重量和大小数据的患者资料。我们的研究纳入了1981年2月至1993年1月期间根据GHSG治疗策略接受分期剖腹术和脾切除术的376例霍奇金淋巴瘤患者。对治疗前临床特征和脾脏重量进行单因素和多因素分析,以预测脾脏受累的可能性。获取了25例患者的计算机断层扫描(CT)图像,并用于关联放射学脾脏大小和病理学脾脏重量。376例患者中有171例发现脾脏受累。脾脏平均重量为258 g(±257),范围为55至3290 g。所有重量超过2000 g的脾脏均显示有病变累及,而重量低于150 g的脾脏从未受累。在多因素分析中,发现脾脏重量(p<0.001)、红细胞沉降率(p<0.001)和临床分期(p<0.01)是脾脏受累的独立预后因素。脾脏重量与通过CT测量的长度、宽度和厚度乘积定义的脾脏指数高度相关(相关系数:0.93)。通过将确定的危险因素应用于临床分期患者,可以确定脾脏受累情况。借助脾脏指数可以估算脾脏重量。指数高于1000时,脾脏受累的概率高于90%。这对于计划接受受累野放疗的患者可能具有极其重要的意义。